Esperion Therapeutics | ESPR - Current Liabilities


Esperion Therapeutics reported $300.81M in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
AbbVie USD 43.29B 3.9B Dec/2025
Alnylam Pharmaceuticals USD 1.47B 89.13M Dec/2025
Alterity Therapeutics Limited AUD 4.38M 849.82K Jun/2023
Amarin USD 194.46M 12.23M Dec/2025
Amgen USD 25.49B 3.7B Dec/2025
Biogen USD 3.35B 59.4M Dec/2025
BioMarin Pharmaceutical USD 759.03M 39.41M Dec/2025
Cipla INR 62.97B 8.13B Sep/2025
CSL USD 4.61B 207M Dec/2025
Cytokinetics USD 202.45M 60.31M Dec/2025
Daiichi Sankyo JPY 778.55B 77.51B Dec/2025
Eli Lilly USD 35.23B 4.91B Dec/2025
Esperion Therapeutics USD 300.81M 58.22M Dec/2025
Geron USD 113.82M 26.11M Dec/2025
Grifols EUR 2.37B 156.97M Dec/2025
Halozyme Therapeutics USD 177.09M 660.14M Dec/2025
Heron Therapeutics USD 96.1M 6.39M Dec/2025
Ionis Pharmaceuticals USD 783M 120.46M Dec/2025
Merck USD 28.63B 2.59B Sep/2025
Minerva Neurosciences USD 2.29M 381K Dec/2025
Moderna USD 1.99B 306M Dec/2025
Nektar Therapeutics USD 66.34M 5.05M Sep/2025
Pfizer USD 36.6B 1.13B Sep/2025
PTC Therapeutics USD 968.43M 102.18M Dec/2025
Puma Biotechnology USD 82.73M 3.63M Sep/2025
Regeneron Pharmaceuticals USD 4.37B 56.7M Dec/2025
Sanofi EUR 28.35B 3.76B Dec/2025
Sarepta Therapeutics USD 1.1B 173.86M Dec/2025
United Therapeutics USD 560.6M 14.3M Dec/2025
Vanda Pharmaceuticals USD 145.16M 27.29M Dec/2025